• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Acorda Therapeutics Inc. (Amendment)

    2/14/22 4:56:07 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACOR alert in real time by email
    SC 13G/A 1 acora3_21422.htm CANYON CAPITAL ADVISORS LLC acora3_21422.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
    Acorda Therapeutics Inc
    (Name of Issuer)
    Common Stock
    (Title of Class of Securities)
    00484M601
    (CUSIP Number)
    December 31, 2021
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 00484M601
           
    1
    NAME OF REPORTING PERSON
    Canyon Capital Advisors LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    95-4688436
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [X]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    649,031
    6
    SHARED VOTING POWER
    7
    SOLE DISPOSITIVE POWER
    649,031
    8
    SHARED DISPOSITIVE POWER
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    649,031
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.79%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 00484M601
           
    1
    NAME OF REPORTING PERSON
    Joshua S. Friedman
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [X]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    649,031
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    649,031
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    649,031
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.79%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: 00484M601
           
    1
    NAME OF REPORTING PERSON
    Mitchell R. Julis
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [X]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    649,031
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    649,031
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    649,031
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.79%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: 00484M601
    ITEM 1(a). NAME OF ISSUER:
    Acorda Therapeutics Inc
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    420 Saw Mill River Road
    Ardsley, NY 10502
    ITEM 2(a). NAME OF PERSON FILING:
    This Schedule 13G is being filed on behalf of the following persons*:
    Canyon Capital Advisors LLC ("CCA")
    Joshua S. Friedman
    Mitchell R. Julis

    CCA is the investment advisor, direct or indirect, to the following persons:
    (i) Canyon Value Realization Fund, L.P. ("VRF")
    (ii) The Canyon Value Realization Master Fund (Cayman), L.P. ("CVRF")


    * Attached as Exhibit A is a copy of an agreement among the persons filing (as specified hereinabove) that this Schedule 13G is being filed on behalf of each of them.
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    The principal business office of the persons comprising the group filing this Schedule 13G is located at
    2728 North Harwood Street, 2nd Floor
    Dallas, TX 75201
    ITEM 2(c). CITIZENSHIP:
    Canyon Capital Advisors LLC - Delaware
    Joshua S. Friedman - United States
    Mitchell R. Julis - United States

    VRF: a Delaware limited partnership
    CVRF: a Cayman Islands exempted limited partnership

    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock
    ITEM 2(e). CUSIP NUMBER:
    00484M601
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    649,031
    (b) Percent of class:
    5.79%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    649,031
    (ii) shared power to vote or to direct the vote:
    649,031
    (iii) sole power to dispose or direct the disposition of:
    649,031
    (iv) shared power to dispose or to direct the disposition of:
    649,031
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    CCA is an investment advisor to various managed accounts, including VRF, and CVRF, with the right to receive, or the power to direct the receipt, of dividends from, or the proceeds from the sale of the securities held by, such managed accounts. Messrs. Friedman and Julis control entities which own 100% of CCA.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not Applicable
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not Applicable
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not Applicable
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 00484M601
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 14 2022
    Canyon Capital Advisors LLC
    By:
    /s/ Doug Anderson
    Name:
    Doug Anderson
    Title:
    Chief Compliance Officer
    February 14 2022
    Joshua S. Friedman
    By:
    /s/ Joshua S. Friedman
    Name:
    Joshua S. Friedman
    Title:
    February 14 2022
    Mitchell R. Julis
    By:
    /s/ Mitchell R. Julis
    Name:
    Mitchell R. Julis
    Title:
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    CUSIP No.: 00484M601
    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING

    The undersigned hereby agree and consent to the joint filing on their behalf of this amendment to Schedule 13G in connection with their beneficial ownership of the common stock of Acorda Therapeutics Inc.
    Dated: February 14, 2022

    CANYON CAPITAL ADVISORS LLC,
    a Delaware limited liability company

    By: /s/ Doug Anderson
    Name: Doug Anderson
    Title: Chief Compliance Officer

    JOSHUA S. FRIEDMAN
    /s/ Joshua S. Friedman

    MITCHELL R. JULIS
    /s/ Mitchell R. Julis


    Get the next $ACOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACOR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACOR
    Financials

    Live finance-specific insights

    See more
    • Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET. The Company does expect to timely file its Annual Report on Form 10-K for the period ended December 31, 2023. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor

      4/1/24 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To participate in the webcast, please use the following registration link: https://events.q4inc.com/attendee/373031481 If you register for the webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the webcast details. On the day of the webcast, you will receive an email 2 hours prior to the start of the webcast with the link to join. The presentation will be

      3/25/24 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Reports Third Quarter 2023 Financial Results

      INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 AMPYRA® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 INBRIJA ex-U.S. revenue of $1.4 million; FAMPYRA royalties of $2.5 million Biopas Laboratories files for approval of INBRIJA in six Latin American countries Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023. "We were pleased to see a 32% increase in new INBRIJA prescription requests in Q3 2023 over Q3 2022. New prescription requests have increased by 38% in the first three quarters o

      11/13/23 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Burns Thomas M.

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 7:59:21 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Burns Thomas M.

      3 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 7:57:11 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Varian John

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 5:38:37 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acorda Therapeutics Announces Delisting from Nasdaq

      Acorda Therapeutics, Inc. today announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company's commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders' equity of at least $10 million. Trading in the Company's common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company's common stock is quoted on the OTC Pink® Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the "ACORQ" ticker symbol. About Acorda Therap

      4/15/24 5:03:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Announces Nasdaq Delisting Notification

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024. The notice follows the Company's April 1, 2024 announcement that it has reached an agreement with Merz Therapeutics to acquire substantially all of the assets of the Company. In connection with that announcement, Acorda and certain of its affiliates filed voluntary petitions to commence Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of New York. Nasdaq commenced proceedings to delist the Company's common stock, based on th

      4/3/24 5:30:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement

      Acorda Files for Voluntary Chapter 11 Protection to Facilitate Orderly Sale Acorda Enters into a Restructuring Support Agreement with over 90% of the Secured Convertible Noteholders Patient Access to INBRIJA® (levodopa inhalation powder) and AMPYRA® (dalfampridine) to Continue Uninterrupted Acorda Therapeutics, Inc. (NASDAQ:ACOR) ("Acorda" or "the Company") today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million. Merz Therapeutics, a leader in the field of neurotoxins, is a business of the global family-owned company Merz, hea

      4/1/24 6:35:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Acorda Therapeutics Inc.

      10-Q - Acorda Therapeutics, Inc. (0001008848) (Filer)

      5/14/24 8:24:14 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K/A filed by Acorda Therapeutics Inc. (Amendment)

      10-K/A - Acorda Therapeutics, Inc. (0001008848) (Filer)

      4/29/24 8:39:11 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Acorda Therapeutics, Inc. (0001008848) (Filer)

      4/25/24 8:00:48 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ACOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Acorda Therapeutics upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Acorda Therapeutics from Neutral to Buy and set a new price target of $10.00 from $5.00 previously

      6/17/21 6:09:07 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Announces Resignation of Chief Operating Officer

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. "We are grateful for Lauren's thirteen years of contributions as a member of Acorda's executive leadership team. Initially, she and her team led the commercial launch of AMPYRA, a novel treatment for multiple sclerosis. The tremendous success of that product allowed Acorda to invest in additional clinical development programs, including INBRIJA for Parkinson's disease," said Ron Cohen, M.D., Acorda's President and CEO. "Lauren has been

      8/19/22 8:00:00 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13D/A - Acorda Therapeutics, Inc. (0001008848) (Subject)

      5/10/23 4:37:39 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13D/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)

      3/10/23 4:15:17 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13G/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)

      2/14/23 4:52:06 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care